KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Change in Account Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Change in Account Payables for 17 consecutive years, with $547.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 3.91% to $547.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 0.03% change, with the full-year FY2025 number at $2.1 billion, changed 0.03% from a year prior.
  • Change in Account Payables was $547.5 million for Q4 2025 at Bio-Rad Laboratories, up from $517.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $620.3 million in Q2 2023 to a low of $446.4 million in Q3 2024.
  • A 5-year average of $544.7 million and a median of $538.8 million in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 30.05% in 2022, then fell 18.67% in 2024.
  • Bio-Rad Laboratories' Change in Account Payables stood at $530.0 million in 2021, then grew by 14.62% to $607.5 million in 2022, then dropped by 14.68% to $518.3 million in 2023, then increased by 1.65% to $526.9 million in 2024, then increased by 3.91% to $547.5 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Change in Account Payables are $547.5 million (Q4 2025), $517.5 million (Q3 2025), and $505.9 million (Q2 2025).